Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.

Meanwhile, Pfizer reckons it's found the right dose for its KAT6.

Herthena-Lung02 data are an ASCO shocker.

Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.

Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.

The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.

A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.